XSWXPPGN
Market cap1.05bUSD
Dec 23, Last price
28.60CHF
1D
-0.52%
1Q
-5.92%
IPO
-64.36%
Name
PolyPeptide Group AG
Chart & Performance
P/E
—
P/S
3.15
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.90%
Rev. gr., 5y
12.27%
Revenues
320m
+14.02%
Net income
-51m
L
CFO
36m
+568.22%
Dividend
Apr 28, 20220.3 CHF/sh
Earnings
Apr 10, 2025
Profile
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 320,372 14.02% | 280,978 -0.41% | 282,126 25.78% | |||
Cost of revenue | 335,955 | 269,678 | 215,274 | |||
Unusual Expense (Income) | ||||||
NOPBT | (15,583) | 11,300 | 66,852 | |||
NOPBT Margin | 4.02% | 23.70% | ||||
Operating Taxes | (6,803) | 200 | 12,590 | |||
Tax Rate | 1.77% | 18.83% | ||||
NOPAT | (8,780) | 11,100 | 54,262 | |||
Net income | (51,440) -762.29% | 7,767 -83.56% | 47,258 50.82% | |||
Dividends | (9,671) | |||||
Dividend yield | 1.16% | |||||
Proceeds from repurchase of equity | 3,265 | 176,677 | ||||
BB yield | -0.39% | -4.01% | ||||
| Debt | ||||||
Debt current | 45,706 | 3,566 | 3,058 | |||
Long-term debt | 91,278 | 30,628 | 28,307 | |||
Deferred revenue | 23,160 | 7,532 | 9,196 | |||
Other long-term liabilities | 36,653 | (9,410) | (10,302) | |||
Net debt | 36,041 | (6,101) | (108,405) | |||
| Cash flow | ||||||
Cash from operating activities | 36,485 | 5,460 | 57,352 | |||
CAPEX | (52,897) | (75,099) | (73,961) | |||
Cash from investing activities | (59,512) | (78,435) | (80,845) | |||
Cash from financing activities | 84,547 | (26,869) | 130,928 | |||
FCF | (23,491) | (77,908) | (42,987) | |||
| Balance | ||||||
Cash | 95,706 | 37,528 | 136,303 | |||
Long term investments | 5,237 | 2,767 | 3,467 | |||
Excess cash | 84,924 | 26,246 | 125,664 | |||
Stockholders' equity | 165,441 | 232,157 | 209,560 | |||
Invested Capital | 469,776 | 450,319 | 359,789 | |||
ROIC | 2.74% | 17.64% | ||||
ROCE | 2.36% | 13.74% | ||||
| EV | ||||||
Common stock shares outstanding | 32,968 | 33,004 | 32,124 | |||
Price | 17.52 -30.81% | 25.32 -81.52% | 137.00 | |||
Market cap | 577,599 -30.88% | 835,661 -81.01% | 4,400,988 | |||
EV | 613,640 | 829,560 | 4,292,583 | |||
EBITDA | 14,886 | 35,326 | 85,565 | |||
EV/EBITDA | 41.22 | 23.48 | 50.17 | |||
Interest | 5,623 | 2,091 | 2,823 | |||
Interest/NOPBT | 18.50% | 4.22% | ||||